IKZF1(plus) alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial

Ito Yoshikiyo; Ozawa Hidetoshi; Eto TetsuyaMiyamoto ToshihiroKamimura TomohikoOgawa RyosukeUchida NaoyukiWake AtsusiFujisaki TomoakiOhno YujuTakase KenOkumura HirokazuTakamatsu YasushiKawano NoriakiAkashi KoichiNagafuji Koji

首页> 外文期刊>European Journal of Haematology >IKZF1(plus) alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial

【24h】

IKZF1(plus) alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial

机译：IKZF1(plus) alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

Objective: The prognostic significance of IKZF1(plus) in adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients had remained to be clarified.Methods: We conducted a prospective, multicenter study, the ALL/MRD2008 trial, and investigated the clinical significance of IKZF1(plus).Results: From December 2008 to November 2013, 38 untreated Ph+ ALL patients were enrolled. At the end of the induction, 97.4 of patients (37/38) achieved complete hematological remission, with MRD-negativity of 48.6 (18/37). There were 19 patients with IKZF1(plus), 13 with IKZF1 deletion alone (Delta IKZF1) and 4 with no IKZF1 deletions (no Delta IKZF1). The probability of 3-year DFS and OS in these Ph+ ALL patients were 50 (95 confidence interval CI, 33-65) and 55 (95 CI, 38-69), respectively. There was no significant difference between IKZF1(plus), Delta IKZF1, and no Delta IKZF1 in DFS (47, 54, 75 p = .63) or OS (47, 62, NA p = .39).Conclusions: We revealed no relationship between IKZF1(plus) status and survival outcomes in Ph+ ALL patients treated with imatinib/dasatinib combination chemotherapy. Further investigations are warranted to clarify the prognostic significance of IKZF1(plus) in adult Ph+ ALL patients.

著录项

来源
《European Journal of Haematology》 |2023年第1期|103-112|共10页
作者
Ito Yoshikiyo; Ozawa Hidetoshi; Eto TetsuyaMiyamoto ToshihiroKamimura TomohikoOgawa RyosukeUchida NaoyukiWake AtsusiFujisaki TomoakiOhno YujuTakase KenOkumura HirokazuTakamatsu YasushiKawano NoriakiAkashi KoichiNagafuji Koji;
展开▼
作者单位

Dept Internal Med,Fukuoka Univ Hosp;

Dept Hematol,Miyazaki Prefectural Hosp;

Grad Sch Med Sci,Kyushu UnivDept Med,Kurume UnivDept Hematol,Imamura Gen HospDept Hematol,Hamanomachi HospDept Hematol,Harasanshin HospDept Hematol & Oncol,Japan Community Hlth Care Org JCHO Kyushu HospDept Hematol,Toranomon Gen HospDept Hematol,Toranomon Hosp KajigayaDept Hematol,Matsuyama Red Cross HospDept Hematol,Kitakyushu Municipal Med CtrDept Hematol,Natl Hosp Org Kyushu Med CtrDept Hematol,Toyama Prefectural Cent Hosp;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类血液及淋巴系疾病;
关键词
IKZF1(plus); Philadelphia-positive ALL; B-CELL PRECURSOR; KINASE DOMAIN MUTATIONS; IMATINIB RESISTANCE; IKZF1 DELETIONS; HYPER-CVAD; PHASE-II; CHROMOSOME; CHEMOTHERAPY; THERAPY; ADULTS;

IKZF1(plus) alterations are not associated with outcomes in Philadelphia-positive acute lymphoblastic leukemia patients enrolled in the FBMTG ALL/MRD2008 trial

摘要

著录项

相关主题

期刊订阅